U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07432308) titled 'Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC' on Feb. 18.
Brief Summary: This interventional study evaluates the clinical utility and feasibility of the Oncomine Precision Assay GX method for genotyping circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer (NSCLC). The study aims to validate this molecular diagnostic approach for potential routine clinical use in detecting relevant genetic alterations from blood samples (liquid biopsy).
Participants with advanced NSCLC will undergo blood sampling as part of the study intervention, and ctDNA will be analyzed using the Onco...